SALT LAKE CITY, Aug. 15, 2024 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be sponsoring, presenting and hosting a booth at the 16th Annual Next Generation Dx Summit, held virtually and in-person in Washington, D.C. on August 19-21, 2024.
Cambridge Healthtech Institute’s Next Generation Dx Summit is described as the nexus for international thought leaders to discuss diagnostic advancement and technology innovation, and offers a valuable window into how point-of-care, decentralized testing, infectious disease, liquid biopsy and companion diagnostics are changing the standard of care.
On Monday, August 19, at 12:15 PM ET, Company CEO Dwight Egan will be presenting on the Company’s forthcoming PCR platform, which is currently under FDA review and is not currently for sale, in a luncheon presentation titled “Co-Dx PCR Platform: The Future of Accessible Diagnostics.”
Attendees are invited to visit the Company at Booth #26 to learn more about the upcoming Co-Dx PCR testing platform as well as the Co-Dx Logix Smart® suite of clinical laboratory solutions. These solutions include Research Use Only (RUO) tests for mpox** virus, one of which was included in a study published in the Oxford Academic journal Open Forum Infectious Diseases in December, 2023. Yesterday, the World Health Organization Director-General declared mpox a public health emergency of international concern (PHEIC).
To learn more about the summit, including in-person and virtual registration details, please visit https://www.nextgenerationdx.com.
*The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not available for sale. The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are currently under review by the FDA and are not available for sale.
**The Co-Dx Logix Smart® Mpox and Co-Dx Logix Smart® Mpox 2-Gene tests are for Research Use Only. Not for use in diagnostic procedures.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to locate genetic markers for use in applications other than infectious disease.
SOURCE Co-Diagnostics
SAN FRANCISCO & BOSTON--(BUSINESS WIRE)--Audax Private Equity (“Audax”) announced today it has entered into a…
Revised system is designed to empower adjuster decision-making and increase productivity SAN DIEGO, Aug. 16,…
Global leader in high-validity real-world evidence for life sciences grows more than 3x in three…
Accelerates ongoing business transformation and sharpens Avantor's strategic focus Strengthens balance sheet with proceeds to…
CodaMetrix’s AI platform, developed with and used by 20 top U.S. health systems, efficiently and…
Celebrated for His Expertise in Breast Augmentation, Facial Rejuvenation and Body Contouring, Dr. Vitenas Continues…